GO
Loading...

Supreme Court Declines Review of Amgen Patent Dispute

The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.

In the latest in a series of major patent cases, the high court declined to review whether a specialized patent appeals court in Washington, D.C., can scrap key patent interpretations made by district court judges during an appeal.

The case is part of Amgen's long-standing patent battle to prevent two other drugmakers from selling a product that would compete with its widely used Epogen anemia treatment.

Amgen in 1997 sued the drugmakers, Hoechst Marion Roussel and Transkaryotic Therapies, in U.S. District Court for the District of Massachusetts, alleging their planned product infringed five Amgen patents. Hoechst, after a merger, is now part of Paris-based Sanofi-Aventis. Transkaryotic has since been acquired by Shire Pharmaceuticals Group of Britain.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • CNBC's Jackie DeAngelis reports gold has hit its lowest level since June, and crude oil dropped $3.08, closing at $92.88 a barrel as traders say geopolitics appears manageable driving prices lower.

  • Discussing the short-term decline in energy prices and how it impacts the equity market, with Lindsey Piegza, Sterne Agee; Hugh Anderson, HighTower; Hank Smith, Haverford Investments; and CNBC's Rick Santelli.

  • Brian Boyle, Boyle Capital president, sees huge opportunity at AIG. Barry James, James Advantage Funds, shares his top stock picks.